ENDRA Life Sciences Inc (NDRA) — Cash Flow-to-Debt Ratio
ENDRA Life Sciences Inc (NDRA) has a Cash Flow-to-Debt Ratio of -0.57x as of June 2026, meaning its operating cash flow of $-927.56K could theoretically repay -1% of its total liabilities ($1.63 Million) in one year. See NDRA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ENDRA Life Sciences Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for ENDRA Life Sciences Inc across 12 annual periods. For the full cash flow conversion analysis, see ENDRA Life Sciences Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for ENDRA Life Sciences Inc (2014–2025)
Year-by-year debt coverage analysis for ENDRA Life Sciences Inc. Check cash flow quality index of ENDRA Life Sciences Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.25x | $-5.18 Million | $1.59 Million | ▲ +16.9% |
| 2024 | -3.91x | $-7.40 Million | $1.89 Million | ▲ +55.1% |
| 2023 | -8.72x | $-9.55 Million | $1.10 Million | ▼ -41.3% |
| 2022 | -6.17x | $-12.77 Million | $2.07 Million | ▼ -16.0% |
| 2021 | -5.32x | $-11.12 Million | $2.09 Million | ▲ +21.2% |
| 2020 | -6.75x | $-10.77 Million | $1.60 Million | ▼ -89.8% |
| 2019 | -3.56x | $-8.59 Million | $2.42 Million | ▲ +55.0% |
| 2018 | -7.90x | $-7.70 Million | $974.58K | ▼ -103.1% |
| 2017 | -3.89x | $-3.30 Million | $848.21K | ▼ -309.5% |
| 2016 | -0.95x | $-1.32 Million | $1.38 Million | ▲ +73.3% |
| 2015 | -3.56x | $-842.73K | $236.42K | ▲ +75.1% |
| 2014 | -14.32x | $-1.40 Million | $97.60K | — |